 | Up a level |
Hughes, KL 
ORCID: 0000-0002-8517-8996, Kirkham, J ORCID: 0000-0003-2579-9325, Clarke, M and Williamson, PR ORCID: 0000-0001-9802-6636
(2019)
Assessing the impact of a research funder’s recommendation to consider core outcome sets.
PLoS One, 14 (9).
e0222418-.
Hill, H
(2016)
Ciprofloxacin Therapy for Neonates and Young Infants:A Clinical Pharmacological Perspective including Pharmacokinetics (PK) and Pharmacodynamics (PD).
PhD thesis, University of Liverpool.
Kottner, J, Jacobi, L, Hahnel, E, Alam, M, Balzer, K, Beeckman, D, Busard, C, Chalmers, J, Deckert, S, Eleftheriadou, V et al (show 10 more authors)
(2018)
Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative.
BRITISH JOURNAL OF DERMATOLOGY, 178 (4).
E279-E285.
Richardson, MH ORCID: 0000-0002-7097-8704, Kirkham, J ORCID: 0000-0003-2579-9325, Dwan, K, Sloan, D, Davies, G ORCID: 0000-0002-3819-490X and Jorgensen, A ORCID: 0000-0002-6977-9337
(2017)
Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol).
Systematic Reviews, 6 (1).
142-.
Richardson, M ORCID: 0000-0002-7097-8704, Kirkham, J ORCID: 0000-0003-2579-9325, Dwan, K, Sloan, DJ, Davies, G ORCID: 0000-0002-3819-490X and Jorgensen, AL ORCID: 0000-0002-6977-9337
(2019)
NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 23 (3).
pp. 293-305.
Cooney, L, Loke, YK, Golder, S, Kirkham, J ORCID: 0000-0003-2579-9325, Jorgensen, A ORCID: 0000-0002-6977-9337, Sinha, I and Hawcutt, D ORCID: 0000-0002-8120-6507
(2017)
Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice.
BMC medical research methodology, 17 (1).
84-.